Published in Oncotarget on July 20, 2015
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget (2016) 0.81
Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells. Oncotarget (2015) 0.81
The Regulation of rRNA Gene Transcription during Directed Differentiation of Human Embryonic Stem Cells. PLoS One (2016) 0.78
Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays (2016) 0.77
CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma. Onco Targets Ther (2016) 0.76
Human Ribosomal RNA-Derived Resident MicroRNAs as the Transmitter of Information upon the Cytoplasmic Cancer Stress. Biomed Res Int (2016) 0.75
Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. Aging (Albany NY) (2016) 0.75
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nat Commun (2017) 0.75
The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. Int J Mol Sci (2017) 0.75
Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. World J Gastroenterol (2017) 0.75
Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways. PLoS One (2017) 0.75
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res (1999) 7.82
Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J (2003) 5.48
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol (2005) 4.89
c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol (2005) 3.79
The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol (2006) 3.31
Nucleolus, ribosomes, and cancer. Am J Pathol (2008) 2.53
Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol Cell (2005) 2.46
The dynamics of postmitotic reassembly of the nucleolus. J Cell Biol (2000) 2.41
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene (2010) 2.25
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res (2010) 2.18
Sensing cellular stress: another new function for the nucleolus? Sci STKE (2004) 2.09
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther (2009) 2.08
Cell cycle-dependent regulation of RNA polymerase I transcription: the nucleolar transcription factor UBF is inactive in mitosis and early G1. Proc Natl Acad Sci U S A (1999) 2.04
Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem (2010) 2.00
Immobilization of proteins in the nucleolus by ribosomal intergenic spacer noncoding RNA. Mol Cell (2012) 1.90
Nucleolar targeting: the hub of the matter. EMBO Rep (2009) 1.82
The moving parts of the nucleolus. Histochem Cell Biol (2005) 1.81
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
Conventional and nonconventional roles of the nucleolus. Int Rev Cytol (2002) 1.43
Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol (2006) 1.39
A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell (2014) 1.35
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis (2012) 1.32
Assembly and disassembly of the nucleolus during the cell cycle. Nucleus (2011) 1.32
The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. J Cell Sci (2008) 1.06
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One (2010) 1.04
Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA. Proc Natl Acad Sci U S A (2013) 1.00
Selective inhibition of rRNA transcription downregulates E2F-1: a new p53-independent mechanism linking cell growth to cell proliferation. J Cell Sci (2011) 0.97
DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response. Oncotarget (2014) 0.82
Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells. Eur J Pharmacol (1994) 0.80